|1.||Seruca, Raquel: 49 articles (10/2015 - 05/2002)|
|2.||Oliveira, Carla: 31 articles (04/2015 - 05/2002)|
|3.||Paredes, Joana: 28 articles (01/2015 - 01/2002)|
|4.||Hirohashi, Setsuo: 26 articles (04/2011 - 01/2002)|
|5.||Höfler, Heinz: 24 articles (05/2012 - 06/2002)|
|6.||Becker, Karl-Friedrich: 23 articles (01/2013 - 06/2002)|
|7.||Schmitt, Fernando: 22 articles (08/2014 - 01/2002)|
|8.||Carneiro, Fátima: 19 articles (10/2015 - 03/2003)|
|9.||Zhang, Wei: 18 articles (01/2016 - 04/2005)|
|10.||Luber, Birgit: 18 articles (01/2015 - 06/2002)|
01/01/2012 - "While the numbers were small and conclusions should be viewed with caution, negative/low E-cadherin expression was associated with improved PFS and OS for hepatobiliary cancers (most significant in HCC) in this refractory patient population where we expected lower expression levels. "
01/01/1997 - "The lost or heterogeneous expression of E-cadherin in tumor tissue was also significantly associated with an increased incidence of tumor recurrence after apparently curative resection, a reduced overall survival rate, and a reduced disease-free patient survival rate. "
10/21/2002 - "Furthermore, absence of either CD103 from the T cells or E-cadherin expression from the cancer cells resulted in a significant reduction in cancer cell lysis. "
10/14/1994 - "A significant reduction in DXR accumulation and cytotoxicity was observed in NM-f-ras-TD-CAMx, which expresses E-cadherin, suggesting that E-cadherin could play a role in the increase of drug resistance observed in confluent cancer cells."
08/01/2013 - "When differentiating the origin of a tumor as either esophageal or pulmonary, an immunohistochemical panel consisting of IMP3, CDX2, and N-cadherin is superior to either TTF-1 or napsin A."
|2.||Neoplasm Metastasis (Metastasis)
06/01/2005 - "Strong E-cadherin expression in lymph node metastases was highly predictive of improved survival. "
01/01/2013 - "Furthermore, SFN treatment resulted in a significant reduction in EMT markers Zeb-1, which correlated with increase in E-Cadherin expression suggesting the blockade of signaling involved in early metastasis. "
06/01/2005 - "A scattergram was generated which identified a subset of patients (25%) with high E-cadherin expression in nodal metastases, and this top quartile had improved survival (P = 0.028). "
06/01/2005 - "On univariate analysis, reduced E-cadherin expression was associated with a reduced disease-free interval and overall survival and also with indicators of poor prognosis including larger tumour size, higher histological grade, development of distant metastasis and tumours negative for oestrogen receptors. "
01/01/2001 - "Therefore, examination of the expression of E-cadherin and Y-K's mode of invasion would be helpful in predicting lymph node metastasis in esophageal SCC."
10/01/2009 - "DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: role of E-cadherin."
12/01/2015 - "The Minimal Carcinoma (MC) Triple Stain is a tri-chromogen multiplex immunostain (CK7, p63, and E-cadherin) helpful in classifying morphologically ambiguous and/or small carcinomas as either ductal or lobular and/or in situ or invasive. "
10/01/2015 - "The present study was planned to explore status of EMT-associated markers ZEB2/SIP1 and E-cadherin in eyelid sebaceous gland carcinoma (SGC) and to correlate with clinicopathological high-risk features. "
07/01/2014 - "The study revealed that the positive PRL-3 expression and abnormal E-cadherin expression were associated with mucinous gastric carcinoma and lymph node involvement. "
03/01/2014 - "The aim of this study is to examine the expression of β-catenin, APC and E-cadherin in tumour tissues of 80 Tunisian patients with gastric carcinoma and to determine the methylation status of the APC promoter in tumour tissues. "
|4.||Breast Neoplasms (Breast Cancer)
12/07/2010 - "the findings support the evidence that high expression values of E-cadherin are not predictive for a good prognosis and may help to explain conflicting evidence on the prognostic impact of E-cadherin in breast cancer when assessed on dichotomic basis."
11/01/2007 - "A progressive and statistically significant reduction of E-cadherin expression was detected in the histologically well- to moderately to poorly differentiated breast cancer cells (p < 0.001). "
05/01/2011 - "E-cadherin immunohistochemistry is helpful in classifying breast cancer cases with indeterminate histopathologic features. "
08/28/2015 - "In the present study, ERα upregulated the expression of the epithelial marker, E-cadherin, in breast cancer cells through the transcriptional down-regulation of Bmi1. "
06/01/2015 - "This study confirmed that FOXA2 inhibited EMT in breast cancer cells by regulating the transcription of EMT-related genes such as E-cadherin and ZEB2. "
11/01/2005 - "The tumoral expression of c-erbB-2 and E-cadherin did not demonstrate a correlation with the staging and degree of cell differentiation, and it did not present prognostic value regarding disease recurrence, disease-free interval, survival and specific mortality among patients with colorectal adenocarcinoma."
09/01/2014 - "We here report the first study to investigate the expression of epithelial-mesenchymal transition (EMT) markers Snail1 and E-cadherin in GEJ adenocarcinoma. "
11/01/2013 - "Recent studies have demonstrated that partial or complete loss of E-cadherin (EC) and nuclear accumulation of zeste homolog 2 (EZH2) are hallmarks of poorly differentiated pancreatic adenocarcinoma (PAC). "
08/01/2013 - "In this study, 24 cases each of pulmonary and esophageal adenocarcinomas were stained with TTF-1, napsin A, CDX2, 34βE12, N-cadherin, and IMP3 in an attempt to define an optimal panel for differentiation. "
03/01/2013 - "In this study, we evaluated the prevalence of abnormal E-cadherin expression in Iranian patients with gastric adenocarcinoma, and tried to find its correlation with H. "
|3.||Messenger RNA (mRNA)
|5.||Biological Markers (Surrogate Marker)
|9.||Syndecan-1 (Syndecan 1)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Transplantation (Transplant Recipients)